Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine. The chemical name for Argatroban is 1-[5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-
8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, monohydrate. Argatroban has 4 asymmetric carbons. One of the asymmetric carbons has an
configuration (stereoisomer Type I) and an
configuration (stereoisomer Type II). Argatroban consists of a mixture of
stereoisomers at a ratio of approximately 65:35.
Argatroban is indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.
Argatroban is indicated as an anticoagulant in patients with or at risk for heparin-induced thrombocytopenia undergoing percutaneous coronary intervention (PCI).
Published Studies Related to Argatroban
Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters. [2011.06]
The synthetic direct thrombin inhibitor argatroban has a rapid onset and offset of anticoagulation. However, there are no data about the pharmacokinetic-pharmacodynamic (PK-PD) relationship of argatroban in patients undergoing contemporary percutaneous coronary intervention (PCI) and no data about other coagulation parameters than activated clotting time (ACT) in this setting...
Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study. [2011.04.14]
CONCLUSION: Argatroban dose-dependently increases coagulation parameters and, compared to UFH, demonstrates a superior predictable anticoagulant effect in patients undergoing elective PCI. Copyright (c) 2010. Published by Elsevier Ireland Ltd.
Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. [2010.04]
CONCLUSION: The results from the PREVENT-HIT study should enhance understanding of the comparative clinical and economic utility of desirudin and argatroban in patients with HIT with or without thrombosis. ClinicalTrials.gov identifier: NCT00787332.
Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin. [2007.02]
CONCLUSIONS: Strenuous exercise enhances platelet and leukocyte activation independently of thrombin. Exercise augments both coagulation and fibrinolysis, but the balance between them appears to be maintained. At therapeutic dosages argatroban counteracted thrombin-induced platelet activation most efficiently, whereas enoxaparin had somewhat stronger anticoagulant and profibrinolytic effects.
A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. [2004.12]
BACKGROUND: We prospectively evaluated 3 treatment regimens of argatroban, a direct thrombin inhibitor, for providing adequate, safe anticoagulation in patients with end-stage renal disease (ESRD) during hemodialysis... CONCLUSION: Argatroban, administered by each treatment regimen, provides safe, adequate anticoagulation to enable successful hemodialysis in ESRD patients. Argatroban dialytic clearance by high-flux membranes is clinically insignificant.
Clinical Trials Related to Argatroban
Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting [Recruiting]
Argatroban is a selective thrombin inhibitor, and previous study had suggested that
argatroban use post PCI could potentially prevent reocclusion. But there has no study on
large sample of argatroban treated restenosis post cranial stenting. This study will test
the safety and efficacy of the argatroban on prevent occlusion and restenosis in patients
with intracranial and extracranial artery stenting.
Argatroban Versus Lepirudin in Critically Ill Patients [Recruiting]
Argatroban TPA Stroke Study [Recruiting]
Is the combination of low doses of argatroban in combination with rt-PA safe, and does it
increase recanalization in patients with acute ischemic stroke.
Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II [Recruiting]
The purpose of this study is to collect data on the clinical management of Argatroban in
patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or
without ongoing thrombosis who require parenteral antithrombotic therapy
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI) [Completed]
This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the
information on dose-response of argatroban in pharmacodynamic markers and to assess the
anticoagulation, safety and efficacy of argatroban in reference to unfractionated heparin, in
combination with dual antiplatelet therapy.
Reports of Suspected Argatroban Side Effects
Cerebral Infarction (10),
Prothrombin Time Shortened (10),
Hepatic Function Abnormal (9),
International Normalised Ratio Increased (8),
Pulmonary Alveolar Haemorrhage (8),
Gastrointestinal Haemorrhage (7),
Activated Partial Thromboplastin Time Prolonged (7),
Pneumonia (7), more >>
Page last updated: 2011-12-09